You might've seen the ticker symbol RMED flickering on your screen a few years back and wondered if it was a solid bet on the future of medical tech. Honestly, the story of Ra Medical Systems Inc is a bit of a rollercoaster, and if you’re looking for the company today, you’re going to find a very different beast than the one that went public in 2018. It wasn’t just another startup; it was a company that held the keys to some pretty cool excimer laser technology. Specifically, they were all about the Pharos system. It was designed to treat dermatological issues like psoriasis and vitiligo, but things got complicated when they tried to pivot hard into the cardiovascular space.
The medical device world is brutal. It’s not just about having a cool laser; it's about navigating the FDA, keeping the lights on through years of clinical trials, and making sure your sales team actually knows how to sell a complex piece of hardware. Ra Medical Systems Inc learned this the hard way. While they had a footprint in dermatology, the real "moonshot" was their D-BRT system for treating peripheral artery disease. It sounded great on paper. Use a laser to blast away plaque in legs. But execution? That's where the wheels started to wobble.
The Rise and High Hopes of Ra Medical Systems Inc
Back in the day, Ra Medical was the scrappy underdog in the excimer laser market. Based out of Carlsbad, California, they were founded in 2002. They spent a long time—almost two decades—refining their tech before the big IPO. When they finally hit the NYSE in 2018, they raised about $66 million. Investors were pumped. The Pharos laser was already being used by dermatologists, and it was widely considered a reliable tool. It was a "known quantity."
But here’s the thing about the stock market: it rarely cares about what you’re doing now. It cares about what you’re doing next. For Ra Medical Systems Inc, the "next" was the DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) catheter. This was meant to be a game-changer for people suffering from chronic total occlusions. Think of it as a tiny, high-tech Drano for your arteries. The problem? The catheter had some reliability issues. Doctors started reporting that it wasn't performing as consistently as it needed to during high-stakes vascular surgeries. When you're poking around inside someone's femoral artery, "mostly reliable" doesn't cut it.
By 2019, the company was facing some serious heat. They had to deal with a voluntary recall of some DABRA catheters. Then came the management shakeups. You've probably seen this script before—founder leaves, interim CEO steps in, and the board starts looking for a "strategic pivot." It was a mess. They were burning cash fast, and the lawsuits started piling up. Investors felt misled about how ready the DABRA system actually was for prime time.
The Pivot That Changed Everything
If you look for Ra Medical Systems Inc today, you won't find a laser company. Not really. In a move that surprised a lot of people who weren't watching the balance sheets closely, Ra Medical decided to merge with Catheter Precision, Inc. in early 2023. This wasn't just a partnership. It was a total transformation. They basically decided that the laser business was too heavy a lift and shifted their focus toward cardiac arrhythmia.
Basically, they traded lasers for VIVO.
👉 See also: Share Market Today Closed: Why the Benchmarks Slipped and What You Should Do Now
VIVO (View Into Ventricular Onset) is a non-invasive 3D imaging system. It helps electrophysiologists figure out exactly where those pesky heart arrhythmias are coming from before they even start a procedure. It's smart. It's niche. And most importantly, it's a lot less capital-intensive than manufacturing and servicing massive excimer laser units. After the merger, the company even changed its name officially to Catheter Precision, though you'll still see the "Ra Medical" name in historical financial filings and older SEC documents.
It’s a classic "Phoenix" story, but the bird that rose from the ashes looks nothing like the one that went into the fire. The old Ra Medical Systems Inc—the one focused on skin lasers and peripheral artery disease—is essentially a legacy chapter now.
Why the Pharos Laser Mattered
Even though the company moved on, we shouldn't dismiss what they did with the Pharos. It was one of the few lasers that could deliver a specific wavelength of light (308nm) that was incredibly effective for autoimmune skin conditions.
- Psoriasis: It could target plaques without hitting the healthy skin around them.
- Vitiligo: It helped stimulate melanocytes to bring color back to white patches.
- Atopic Dermatitis: It provided relief for patients who were failing on topical steroids.
The tech worked. It really did. But in the medical device industry, "working" is only half the battle. You have to be able to manufacture it at scale, keep your margins high, and defend your patents against giants like STRATA Skin Sciences. Ra Medical found themselves in a perpetual legal and competitive squeeze.
What Investors and Med-Tech Observers Can Learn
The story of Ra Medical Systems Inc is a masterclass in the dangers of the "bridge too far." They had a solid, albeit smaller, business in dermatology. They tried to bridge over into the high-stakes, high-reward world of cardiovascular intervention without having the infrastructure to support it.
The FDA's 510(k) clearance process is often misunderstood by casual observers. Just because a device is cleared doesn't mean it's going to be a commercial success. It just means it's "substantially equivalent" to something already on the market. Ra Medical got their clearance, but they didn't have the clinical data to convince skeptical vascular surgeons to ditch their existing tools for the DABRA system.
✨ Don't miss: Where Did Dow Close Today: Why the Market is Stalling Near 50,000
Honestly, it’s a cautionary tale about R&D. You can’t just throw money at a technical problem and hope it goes away by the next quarterly earnings call. The reliability issues with the DABRA catheters weren't just "bugs"—they were fundamental engineering challenges that required more time and money than the company's burn rate allowed.
The Legal Headache
We have to talk about the Department of Justice. In 2022, Ra Medical had to settle for about $2.5 million regarding allegations that they were involved in a kickback scheme. The feds alleged that the company was paying doctors to use the DABRA system under the guise of "consulting fees" or "data collection."
They didn't admit to any wrongdoing, but that kind of headline is a death knell for a small cap company trying to gain trust. It makes it nearly impossible to raise more capital on favorable terms. When you combine legal fees, settlement costs, and a tanking stock price, a merger becomes the only way to survive.
The Reality of RMED Today
If you're looking at the ticker now, you're looking at Catheter Precision (VTAK). The legacy of Ra Medical Systems Inc is mostly found in the tax loss carryforwards and the corporate shell that allowed Catheter Precision to get onto a public exchange faster.
Is the technology still around? Sort of. Some of the dermatological assets were spun off or sold. If you're a patient looking for a Pharos treatment, those machines are still out there in the wild, being serviced by third parties or the companies that acquired the remnants of that division. But as a corporate entity, the Ra Medical we knew is gone.
Understanding the Cardiovascular Fail
Why did the laser fail in the arteries when it worked on the skin? Physics. The environment inside a pulsating artery is vastly different from the surface of the skin.
🔗 Read more: Reading a Crude Oil Barrel Price Chart Without Losing Your Mind
- Vessel Tortuosity: Leg arteries aren't straight pipes; they twist and turn. The early DABRA catheters were often too stiff or too fragile to navigate those turns.
- Heat Management: Lasers generate heat. If you get it wrong, you don't just clear the blockage; you damage the vessel wall.
- Competition: They weren't just fighting biology; they were fighting Boston Scientific and Medtronic. Those guys have infinite budgets and sales reps in every hospital in the country.
Actionable Insights for Following the Sector
If you’re interested in the remnants of this tech or the medical device space in general, here is how you should actually look at these companies so you don't get burned like the early RMED investors.
Look at the "Utilization" over "Placement."
Don't just look at how many machines a company like Ra Medical sells. Look at how often they are used. A machine sitting in a corner gathering dust doesn't generate "consumable" revenue. Ra Medical struggled because even when they placed a laser, doctors weren't using the catheters as often as predicted.
Watch the "Clinical Moat."
Does the company have unique clinical data, or are they just a "me too" product? Ra Medical lacked the massive, multi-year randomized controlled trials that the big players use to lock down the market. If you're tracking a new med-tech firm, check their PubMed presence. If it's thin, be careful.
Audit the Management’s History.
When the original team at Ra Medical started leaving, that was the signal. In med-tech, the "founding genius" is often great at the invention but terrible at the commercialization. You want to see a "commercial-heavy" CEO step in when it's time to scale.
Follow the Patents.
Even when a company like Ra Medical Systems Inc fails or merges, the patents still have value. Sometimes the best way to play these situations is to look at who buys the IP. Intellectual property is the only thing that survives a corporate bankruptcy or a fire-sale merger.
The saga of Ra Medical is basically a reminder that in the world of medical technology, having a great "light bulb" doesn't matter if you can't figure out how to screw it in. They had the light, but the socket was just too complex.
Next Steps for Research
Check the latest 10-K filings for Catheter Precision (VTAK) to see how they are handling the legacy liabilities of Ra Medical. You should also look up the FDA MAUDE database for any recent reports on the Pharos or DABRA systems if you are a clinician or a patient—this database tracks all medical device "events" and gives you the unvarnished truth about equipment performance in the field. Finally, if you're an investor, look into STRATA Skin Sciences (SSKN); they are the primary competitor that ended up absorbing much of the market share that Ra Medical once chased.